Another study found synergistic effects of ruxolitinib, a JAK1/2 inhibitor, and vorinostat, a histone deacetylase (HDAC) inhibitor, in treating JAK2V617F-positive myeloproliferative neoplasms (MPNs). This evidence concerns the gene HDAC9 and myeloproliferative neoplasm.